TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03859843

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Ten mL of venous blood will be drawn in a syringe fill with 1.5 mL of anticoagulant solution (anticoagulant citrate dextrose solution formula A, Baxter, Deerfield, IL). The blood will be centrifuged at 160 g for 10 minutes. After the first spin, the lower red blood cell portion will be discarded, and the supernatant will be centrifuged at 400 g for 10 minutes. The resulting pellet of platelets will be mixed with 1.5 mL of supernatant, which make 1.5 mL of PRP. One mL of 3% calcium chloride will be added to the PRP to induce platelet activation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemical peeling (Salycilic acid)
Description: SA is a 2-hydroxybenzoic acid (from willow tree) used for superficial peeling due to its strong keratolytic and comedo- lytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum.19 These chemical properties explain its popularity and success in acne patients.It also has well- documented anti-inflammatory properties.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemical peeling (Jessener's solution)
Description: is a superficial peeling agent used as adjuvant therapy for acne. it is generally proposed to break of the hydrogen bonds of keratin (keratolysis), disruption of cell membranes (cell death) and is bactericidal.
Study: NCT04156607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: For the fascia technique, one part of the band which were divided by 4 fans is adhered on Achilles tendon to the heel with a 0% stretch. Then the plantar fascia was stretched by the examiner and the toes were extended (ankle dorsiflexion, toe extension) and the divided part of the band was applied toward the metatarsal heads with paper-off technique (5-15%).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: ''I'' bant were cut from the middle point of the Achilles tendon to the metatarsal heads. The band was applied from the Achilles tendon to the metatarsal heads without any stretching of plantar fascia and band.
Study: NCT02323295

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (Non-surgical Arm)
Description: Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Malignant Tumor Surgery
Description: Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor
Study: NCT02627365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized, interactive short messaging intervention
Description: An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
Study: NCT02144493

Intervention type: OTHER
Intervention: The existence of periampullary diverticulum
Description: Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.

Intervention type: OTHER
Intervention: The existence of periampullary diverticulum
Description: Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.

Intervention type: OTHER
Intervention: CBD angle
Description: Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone

Intervention type: OTHER
Intervention: CBD angle
Description: Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
Study: NCT01051622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labeling Ceretec
Description: Technetium-99m is used to radiolabel cells of interest i.e PBMC's

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labeling Ceretec
Description: Technetium-99m is used to radiolabel cells of interest i.e PBMC's
Study: NCT03229382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
Study: NCT01907724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: IDX719 will be supplied as a 50 mg tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: IDX719 will be supplied as a 50 mg tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 mg capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 mg capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: TMC647055 will be supplied as 150 mg capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: TMC647055 will be supplied as 150 mg capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: RTV will be supplied as 80 mg/mL solution for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: RTV will be supplied as 80 mg/mL solution for oral administration.
Study: NCT00700284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vaginal ring
Description: vaginal ring containing no TMC120 (dapivirine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC120 (dapivirine) vaginal ring
Description: vaginal ring containing 120 mg TMC120 (dapivirine)
Study: NCT01848652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion of MYOCET
Study: NCT03047954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Description: BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Matching Placebo capsule administered
Study: NCT02599883

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Dose Computed Tomography
Description: Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
Study: NCT01991977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo DTI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluorodopa
Description: Undergo 18F-DOPA-PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Magnetic Resonance Imaging
Description: Undergo pMRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-DOPA-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Receive temozolomide
Study: NCT00703378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Description: Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Description: Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Description: Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
Study: NCT02838290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction
Description: Participants will be randomly assigned (computer generated straight away after clicking the link to the research) to one of 4 experimental conditions: stress at work, dealing with a patient's death, managing stress at work or all topics together. Each module includes brief reflection parts and quizzes. Participants will be asked to fill in an online survey just before the induction and a week after. The survey is about current occupational distress and organizational factors.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Participants in the control group will be asked to fill in an online survey, but will not have any task at time-1. However, participants in the control group will be invited to complete induction programme after time-2 (a week time after time-1) in ensure the same expectations in both, experimental and control, groups.
Study: NCT02878278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide BIW
Description: Chidamide is given 30mg, twice a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide QD
Description: Chidamide is given 10mg,QD
Study: NCT02866019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLS2702C/CLS2702D
Description: CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month \[16 days\]; transplantation period, assessment/follow-up period, 6 months \[24 weeks\])
Study: NCT02958878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Study: NCT02722824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electro-stimulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00804349

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autotitrating Positive Airway Pressure
Description: Patients will be treated with Autotitrating Positive Airway Pressure therapy
Study: NCT04372966

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.
Study: NCT03525353

Intervention type: OTHER
Intervention: Endoscopic retrograde cholangiopancreatography - No Intervention have been used other than standard of care
Description: No intervention has been used and this is an observational study
Study: NCT02382978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-provided well child visit
Study: NCT01353924

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bet v 1aF1-Alum + Bet v 1aF2-Alum
Description: subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Alum-Placebo
Description: subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
Study: NCT02356081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASyMS intervention Group
Description: ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
Study: NCT01224210

Intervention type: DRUG
Group type: OTHER
Intervention: Ambrisentan
Description: Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
Study: NCT01637961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03418077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: Participants will consume a randomly assigned single 24 oz can of an original flavor energy drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-control
Description: Participants will consume a randomly assigned single 24 oz can of control drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
Study: NCT01517334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline HCl Microspheres
Study: NCT01159769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
Description: Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
Study: NCT04733131

Intervention type: DRUG
Intervention: Conversion to a belatacept regimen
Description: belatacept intravenous on Days 1, 15, 29, 43, 57 then every 28 days.
Study: NCT02947282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Workshop
Description: They will attend a 2 hour class on pelvic floor health
Study: NCT01846247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care + VEM
Description: Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Study: NCT01140269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCR test
Description: PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
Study: NCT00931567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous platelets gel
Description: Application of autologous platelets gel (Platelet Rich Fibrin) after the  open palm  surgical treatment of Dupuytren's disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaselitulle
Description: application of standardized wound dressing after the  open palm  surgical treatment of Dupuytren's disease.
Study: NCT01146730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workcoping and IPS
Description: Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
Study: NCT04122300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euphrasia Officinalis Preparation
Description: At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
Study: NCT01146730

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary care by GP or NAV
Description: Ordinary care by the participants physician or the local Labour and Welfare Administration
Study: NCT01677442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-intubated thoracic epidural anesthesia
Description: VATS under no-intubated thoracic epidural anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double-lumen endotracheal intubated anesthesia
Description: VATS under double-lumen endotracheal intubated anesthesia
Study: NCT01735591

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 capsule a day from inclusion until the date of liver transplantation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Capsules with 3x10\^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
Study: NCT01335243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Transforaminal Lumbar Interbody Fusion (TLIF) surgery
Description: The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
Study: NCT00650559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest wall enlargement
Description: Widening sternotomy
Study: NCT03610178

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life-style modification, insulin therapy if needed
Description: All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.1 mmol/L fasting and \<7.0 mmol/L postprandial) are not achieved insulin therapy is started

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life-style modification, insulin therapy if needed
Description: All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.1 mmol/L fasting and \<7.0 mmol/L postprandial) are not achieved insulin therapy is started

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life-style modification, insulin therapy if needed
Description: All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.3 mmol/L fasting and \<7.8 mmol/L postprandial) are not achieved insulin therapy is started

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life-style modification, insulin therapy if needed
Description: All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.3 mmol/L fasting and \<7.8 mmol/L postprandial) are not achieved insulin therapy is started
Study: NCT04959110

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic study
Description: * Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L~* Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium~* In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic study
Description: * Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L~* Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium~* In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter
Study: NCT02980367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Surgical Management (Rehabilitation)
Description: Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
Study: NCT03103659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalised care plan
Description: Quality of life assessement in elderly cancer patients
Study: NCT01918111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine infusion treatment
Description: Continue hypertensive medication